Summary
We have previously shown that human liver myofibroblasts promote in vitro invasion of human hepatocellular carcinoma (HCC) cells through a hepatocyte growth factor (HGF)/urokinase/plasmin-dependent mechanism. In this study, we demonstrate that myofibroblasts synthesize the serine proteinase inhibitor tissue factor pathway inhibitor-2 (TFPI-2). Despite the fact that recombinant TFPI-2 readily inhibits plasmin, we show that it potentiates HGF-induced invasion of HCC cells and is capable of inducing invasion on its own. Furthermore, HCC cells stably transfected with a TFPI-2 expression vector became spontaneously invasive. HCC cells express tissue factor and specifically factor VII. Addition of an antibody to factor VII abolished the pro-invasive effect of TFPI-2. We suggest that TFPI-2 induces invasion following binding to a tissue factor/factor VIIa complex preformed on HCC cells. Our data thus demonstrate an original mechanism of cell invasion that may be specific for liver tumor cells.
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Hepatocellular carcinoma (HCC 1 ) is one of the most frequent primary tumors in the world (1). It is a major complication of liver cirrhosis, although more rarely it will develop on a non-cirrhotic liver. HCC are characterized by a high rate of local, intra-hepatic invasion. HCC are infiltrated by myofibroblast-like cells, located around tumoral sinusoids and in fibrous septa and capsule, when present (2) (3) (4) . We have previously shown that cultured human liver myofibroblasts strongly promoted in vitro invasion of human HCC cell lines through their secretion of hepatocyte growth factor (HGF) (5) . In further studies, we showed that HGF induced invasion by increasing the expression of the urokinase-type plasminogen activator (uPA) by the cancer cells (6) . Indeed, myofibroblasts-or HGF-induced invasion was dose-dependently blocked by a selective uPA antagonist (6) . One of the main functions of uPA is to convert the inactive zymogen plasminogen into plasmin, a broad-spectrum proteinase able to degrade several components of the extracellular matrix and thus a likely effector of cancer cell invasion.
Tissue factor pathway inhibitor-2 (TFPI-2), also known as placental protein 5 is a serine proteinase inhibitor containing 3 tandemly arranged Kunitz-type proteinase inhibitor domains, homologous to tissue factor pathway inhibitor (7). TFPI-2 exists as 3 isoforms of 27, 31 and 33 kD that are synthetic products of a single gene and arise from differential glycosylation. TFPI-2 is a strong inhibitor of plasmin as well as of trypsin, plasma kallikrein and factor XIa. It does not inhibit uPA (8) . TFPI-2 synthesis has been described in dermal fibroblasts and endothelial cells (9) (10) (11) . In these cell types, the major part of TFPI-2 is sequestered within the extracellular matrix (ECM), presumably bound to heparan sulfate. In the course of a systematic sequencing of a human liver Neaud et al.
myofibroblasts cDNA library described elsewhere (12), we found that these cells expressed transcripts for TFPI-2. Given the ability of TFPI-2 to inhibit plasmin, we were interested in defining the contribution of myofibroblasts-derived TFPI-2 in regulating the pro-invasive effect of these cells towards HCC cells.
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Experimental procedures
Recombinant proteins and antibodies-Human recombinant rTFPI-2 was expressed in BHK cells and purified as previously described by a series of chromatographic steps (7) . Human recombinant HGF was a generous gift from Dr. George Vande Woude (NCI, Frederick, MD). An affinity-purified anti-human factor VII IgG was prepared as described (13) by applying a redissolved 50% ammonium sulfate pellet from rabbit antifactor VII antiserum to a recombinant factor VIIa-Affi-Gel 15 column equilibrated with TBS and eluting with 0.1 M glycine-HCl (pH 2.5)/0.5 M NaCl into a 1/10 volume of 1M Tris-HCl (pH 8.8) to immediately neutralize the glycine.
Cells-HepG2, HuH7 and Hep3B human HCC lines were cultured in Dulbecco's modified Eagle's medium (DMEM, GIBCO-BRL, Life Technologies, Cergy-Pontoise, France) containing 10% fetal calf serum (FCS,GIBCO-BRL). HT1080 cells, derived from a human fibrosarcoma, were obtained from the American Tissue Type Culture Collection and grown as the HCC cell lines. Human hepatic myofibroblasts were obtained from explants of non-tumoral liver resected during partial hepatectomy as previously described (14) . Isolated cells were characterized as myofibroblasts as previously described in detail (14, 15) . Specifically, the procedure, that is based on the selective growth advantage of myofibroblasts in the culture conditions used, allowed for a 100% pure myofibroblast population, as shown by positive staining for smooth muscle alphaactin and vimentin, and negative staining for CD 68 (a Kupffer cell marker), von Willebrand factor (an endothelial cell marker), or cytokeratin (an epithelial cell marker) (not shown). This procedure is in accordance with INSERM ethical regulations imposed by French legislation. Myofibroblasts were grown in DME containing 5% FCS, 5% Northern blot-Total RNA was prepared using the Qiagen RNeasy kit. Ten µg were analyzed by Northern blot as described (6) . The probe used was the full length human TFPI-2 cDNA (7) and was labeled with [α 32 P]dCTP by random priming using the Ready-to-go kit from Boehringer-Mannheim (Meylan, France).
Reverse-transcription polymerase chain reaction-1 µg total RNA was reverse- GCC CA-3'), factor VII sense (5'-GGA TGC ACA CAC AGA TGG TC-3'), factor VII antisense (5'-ACA GCA CAC ATG GAG TCA GC-3'). The size of the predicted product is 296 bp for tissue factor, and 295 bp for factor VII. ß2-microglobulin was used as a positive control for RNA integrity and reverse transcription efficiency.
Detection of TFPI-2 protein expression-To prepare extracellular matrix (ECM) extracts for Western blotting, cells were grown to confluence, washed twice with serumfree DME, and incubated for 24 h in the same medium. The ECM was prepared as For metabolic labeling, cells were grown to confluence in 35-mm dishes. They were washed and incubated for 6 h in 1 ml methionine-cystine-free DME containing 0.25 Immunoprecipitates were collected with protein A-Sepharose. They were washed as described (16) and eluted by boiling in 2-fold concentrated reducing loading buffer.
They were run on 10% polyacrylamide gels. Gels were stained, destained, dried and exposed for autoradiography. with serum-free DME and incubated overnight in serum-free DMEM. They were then stimulated for various times with rTFPI-2 in 0.8 ml DMEM. At the end of the incubation, the dishes were put on ice, washed twice with ice-cold PBS containing 10 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin A, 1 mM Pefabloc, 1 mM sodium orthovanadate, 10 mM ß-glycerophosphate, final concentrations. The cells were finally lysed in RIPA buffer with added 0.25%deoxycholate (w/v) and phosphatase inhibitors. Fig.1) . No TFPI-2 antigen could be detected in myofibroblast culture medium by this technique. However, using metabolic labeling and immunoprecipitation, TFPI-2 was observed in both cell/ECM extracts and in culture medium. Specificity was demonstrated by the absence of signal in samples precipitated with control IgG.
Recombinant TFPI-2 has pro-invasive properties˙We have previously shown that myofibroblasts-induced invasivity was dependent on secretion of HGF by myofibroblasts, and could be reproduced by rhHGF through an uPA-dependent pathway (6) . As HepG2 cells do not produce any detectable TFPI-2, we thus tested whether exogenous rTFPI-2 would counteract HGF-induced invasion of HepG2 cells. Surprisingly, TFPI-2 (50 nM) potentiated the effect of HGF on invasion ( Fig. 2A) . This (Fig. 3B) or kinetics study (5 min-1 h) (not shown) whereas HGF used as positive control was highly active.
Interestingly, TFPI-2 abolished the anti-proliferative effect of HGF, even at the lowest concentration tested (5 nM) (Fig. 3A) .
To rule out the possibility that the pro-invasive effect of TFPI-2 was due to a contaminant carried over through the purification of the recombinant molecule, we repeated the experiments in the presence of an anti-TFPI-2 antibody. At a concentration of 50 µg/ml, the specific TFPI-2 antibody inhibited by 49.4 ± 11.3 % the invasion induced by 50 nM TFPI-2 (n = 5). Control IgG at the same concentration produced only a 6.5 ± 4.7 % inhibition. Furthermore, we established stable clones of HepG2, transfected with a TFPI-2 expression vector. Expression of TFPI-2 was verified by RT-PCR (not shown), Western blotting (Fig. 4A), and immunoprecipitation (Fig. 4B) .
One clone that expressed high levels of TFPI-2 was further studied, together with a clone transfected with an empty vector (Fig.4C) . The TFPI-2-expressing clone was significantly more invasive than the clone containing the empty vector (p=0.018, Kruskal-Wallis test). The invasivity of this clone could be blocked with anti-TFPI-2 IgG (58 and 42 % inhibition with 50 µg/ml antibody in 2 separate experiments), but not control IgG (respectively 10.5 and 6 % inhibition). Invasive activity of the control clone could be enhanced by exogenous rTFPI-2, showing that this clone still retained its sensitivity to TFPI-2 (Fig 4C) . 
Factor VII is involved in the pro-invasive effect of TFPI-2˙RT-PCR analysis showed
that HepG2 cells expressed transcripts for factor VII, as well as for tissue factor. On the other hand, HT 1080 cells did not express detectable factor VII transcripts (Fig. 5A ). An antibody to factor VII dose-dependently blocked the pro-invasive effect of TFPI-2 on HCC cells, whereas a non immune IgG was uneffective (Fig. 5B) . The antibody effect was highly significant by ANOVA (p = 0.0002).
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Discussion
Invasion is a characteristic feature of HCC. In previous studies, we have shown that tumor-associated myofibroblasts strongly promoted in vitro invasion of HCC cells through a HGF/uPA mechanism (5,6). The proteolytic pathway of invasion is dependent on the balance of many components including among others serine proteinases such as uPA and plasmin, matrix metalloproteinases, and proteinase inhibitors (18) (19) (20) . The latter include well-characterized proteins such as the tissue inhibitors of matrix metalloproteinases (TIMPs) and the plasminogen activator inhibitors (PAI) 1 and 2. TFPI-2 has been recently recognized as identical to placental protein 5, a serine proteinase inhibitor. We have shown that rTFPI-2 strongly inhibited the in vitro invasion of the highly invasive HT1080 cell line, presumably through plasmin inhibition (21) . In this study, we demonstrate that cultured human liver myofibroblasts synthesize TFPI-2 and secrete it, mainly in their ECM. We were thus interested to know whether TFPI-2 regulated the invasivity of HCC cells that involves uPA and plasmin. We tested the effect of exogenous, rTFPI-2, on the invasion of HCC cells that do not synthesize detectable TFPI-2. In our experimental conditions, human HCC cell lines are spontaneously poorly invasive. In these experiments, invasion was induced by addition of rhHGF that mimics the co-culture with myofibroblasts, as described previously (5) . Surprisingly, rTFPI-2 did not decrease invasion in these conditions. On the contrary, it had an additive effect with HGF. Moreover, rTFPI-2 in the absence of HGF induced dose-dependently an invasive activity. These effects were observed with 3 different human HCC cell lines. Several arguments rule out the possibility that this effect was due to a contaminant carried over through the Neaud et al. purification of rTFPI-2 : first, the effect of rTFPI-2 was blunted by an anti-TFPI-2 antibody; second, HCC cells stably transfected with a TFPI-2 expression vector are more invasive spontaneously that control-transfected cells. As transfected HepG2 cells express the 3 differently glycosylated isoforms, this latter result also argues against the hypothesis that the lack of anti-invasive effect of rTFPI-2 was due to the absence of the lower molecular weight species from the recombinant preparation. Altogether, these results suggested that TFPI-2 could have both an anti-invasive effect, probably indirect and mediated via plasmin inhibition, as well as a direct pro-invasive effect. Other proteinase inhibitors share such a dual effect. PAI-1, as an inhibitor of plasminogen activation, has anti-invasive properties. On the other hand, it can displace the binding of the uPA receptor to vitronectin, thus allowing cell migration and invasion (22) . This has been nicely demonstrated in vivo using PAI-1 -/-mice that show impaired tumor invasion (23). TIMP-2 inhibits MMP-2 activity and can thus reduce ECM breakdown and invasion. However, it also participates in the ternary activation complex of pro-MMP-2, together with MT1-MMP and can thus increase MMP-2 activity (24).
Our data also suggest a mechanism for the pro-invasive effect of TFPI-2. It has recently been shown that the TFPI-2 homolog, TFPI-1, could induce the migration of tissue-factor expressing bladder tumor cells in the presence of exogenous factor VIIa (25) . We reasoned that TFPI-2 could have the same property and that HCC cells, being derived from hepatocytes, were the only tumor cell type with the ability to synthesize factor VII themselves. We have confirmed this expression, as well as that of tissue factor by RT-PCR. On the other hand, HT 1080 cells, which invasion is inhibited by TFPI-2 and supernatants (3, 4) were immunoprecipitated with an antibody to TFPI-2 (1, 3) or a non specific IgG (2, 4). 
